Fecal Noninvasive Biomarkers Oriented Control Versus Usual Care Strategy in Ulcerative Colitis

Design: Multicenter, Open-Label, Randomized, Parallel Controlled Allocation: 1:1 Randomization Masking: Open-label (outcome assessors blinded for endoscopy) Primary Purpose: Treatment Strategy Evaluation Phase: Phase IV (Post-Marketing Surveillance)

NCT Number	NCT07402135
Lead Sponsor	Qilu Hospital of Shandong University Collaborators: Qilu Hospital of Shandong University (Qingdao), Dezhou Hospital Qilu Hospital of Shandong University, Weihai Municipal Hospital, Jining First People's Hospital, Zaozhuang Municipal Hospital, Liaocheng People's Hospital, Weifang People's Hospital
Conditions	Noninvasive Biomarkers, Ulcerative Colitis (UC)
Enrollment	240 participants
Start Date	2026-02-10
Primary Completion	2026-08-30 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-11